Thu, Nov 27, 2014, 6:00 AM EST - U.S. Markets closed for Thanksgiving Day


% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • cash2go cash2go Mar 26, 2013 4:43 PM Flag

    Holding $10 plus. More coverage coming?

    What will analyst see? First things first:

    About Ovarian Cancer
    80% of all ovarian cancers are folate-positive, 40% are folate positive in 100% of tumors. Vintafolide in the 100% positive tumors show PFS extended 50% and overall survival extended 63.6 versus 41.7 weeks.

    Meanwhile Merck if focused on NSCLC results that look like a slam dunk, thus the early buyout threat.

    GLTA, the recent Analyst day Presentation is worth the read for anyone new to our $10 stock.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • from the Analyst day Presentation:

      So this is essentially very common that the next step we should do is in combination with taxol and carbo, so that we can move the line of treatment of vintafolide into first line ovarian as well as in non-small cell lung cancer. This study is actually being done a by our Merck colleague and ((has already started)).

      • 1 Reply to cash2go
      • next generation Tubulysin, they actually used the word cure:

        vintafolide...just not enough receptors to deliver enough of that warhead.... We see curative activity at dose levels where vintafolide is completely inactive so low dose levels. You don't have to saturate all the receptors on these particular cells with the folate tubulysin SNBC. It’s confirmed to be active against naturally occurring vintafolide resistant cancer. This is really unique, because it extrapolates this to the clinical setting. If a patient progresses on vintafolide, we already know and we mentioned this before the break that the receptors persist. The receptors persist even though a patient may progress.

6.570.000(0.00%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.